查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1616236

多種癌症早期檢測市場機會、成長動力、產業趨勢分析與預測 2024 - 2032

Multi Cancer Early Detection Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 93 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023 年，全球多種癌症早期檢測市場價值為13 億美元，預計2024 年至2032 年複合年成長率為14.8%。 。數據顯示，早期檢測可以將某些癌症類型的存活率提高高達 90%。提高公眾意識正在推動多種癌症早期檢測測試的採用。領先的製藥和生物技術公司正在與診斷公司合作開發和推廣 MCED 測試。

這些合作夥伴關係對於將新技術引入市場並確保其廣泛接受至關重要。根據測試類型，NGS技術支援多種基因panel和LDT，從而能夠對眾多基因進行快速定序。其高通量、準確性和不斷下降的成本奠定了其在 MCED 市場的主導地位。這些工具適用於多種癌症，為癌症診斷提供了顯著的多功能性。

他們透過一次測試識別多種癌症類型的能力增強了他們在 MCED 市場的價值。開發基因組和 LDT 的公司已經在診斷領域佔據了重要地位。他們對製藥和生物技術領域的研發和策略聯盟的關注鞏固了他們在 MCED 領域的領導地位。基因組學和分子生物學的進步不斷推動基因組和 LDT 的發展。

市場範圍
開始年份 2023年
預測年份 2024-2032
起始值 13億美元
預測值 47 億美元
複合年成長率 14.8%

這種持續的創新使這些工具始終處於癌症檢測的最前沿，並鞏固了它們在 MCED 市場中的地位。多癌症早期檢測市場依最終用途分為醫院、診斷實驗室和其他最終用戶。 2023 年，醫院佔據市場主導地位，市佔率為 48.2%。患者經常去醫院進行常規健康檢查、診斷和癌症篩檢。

這使得醫院成為將 MCED 測試整合到既定醫療保健工作流程中的理想場所。醫院擁有多學科團隊，包括腫瘤學家、病理學家、遺傳學家和其他專家，他們協作解釋和應用 MCED 測試結果。這種團隊合作增強了早期檢測工作並改進了治療計劃。 2023 年，北美在多癌症早期檢測市場處於領先地位，收入達 5.189 億美元。

對次世代定序（NGS）和液體活體組織切片技術的大量投資推動了這一主導地位。 FDA 對多項 MCED 測試的突破性設備指定強調了有利的監管環境，簡化了這些測試的開發和批准。患者意識的提高和對早期癌症檢測解決方案不斷成長的需求進一步加強了該地區在全球多癌症早期檢測市場的領導地位。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 癌症盛行率增加
      • 高癌症檢出率加上對有效癌症工具的需求不斷成長
      • 癌症篩檢中資料分析和人工智慧 (AI) 的進步
    • 產業陷阱與挑戰
      • 多癌篩檢檢測費用高
  • 成長潛力分析
  • 監管環境
  • 管道分析
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

  • 主要趨勢
  • 基因組、LDT 等
  • 液體活體組織切片

第 6 章：市場估計與預測：按最終用途分類，2021 - 2032 年

  • 主要趨勢
  • 醫院
  • 診斷實驗室
  • 其他最終用戶

第 7 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 8 章：公司簡介

  • AnPac Bio-Medical Science Co., Ltd.
  • Burning Rock Biotech Limited
  • EarlyDiagnostics
  • Elypta AB
  • EXACT SCIENCES CORPORATION
  • Freenome Holdings, Inc.
  • Genecast Biotechnology Co., Ltd.
  • Guangzhou AnchorDx Medical Co., Ltd.
  • GUARDANT HEALTH, INC.
  • Illumina, Inc. (GRAIL, Inc.)
  • Micronoma, Inc.
  • Oncocyte Corporation
  • Roche Holdings, Inc (FOUNDATION MEDICINE, INC.)
  • SeekIn Inc.
  • Singlera Genomics Inc
簡介目錄
Product Code: 11171

The Global Multi Cancer Early Detection Market, valued at USD 1.3 billion in 2023, is projected to grow at a CAGR of 14.8% from 2024 to 2032. Campaigns and educational initiatives by governments and non-profits have increased public awareness about the importance of early cancer detection. Data shows that early detection can improve survival rates by up to 90% for certain cancer types. Improving public awareness is driving the adoption of multi-cancer early-detection tests. Leading pharmaceutical and biotechnology companies are collaborating with diagnostic firms to develop and promote MCED tests.

These partnerships are crucial for introducing new technologies to the market and ensuring their widespread acceptance. By test type, NGS technology supports several gene panels and LDTs, enabling the rapid sequencing of numerous genes. Its high throughput, accuracy, and declining costs have established its dominance in the MCED market. These tools are applicable to a wide range of cancers, offering significant versatility in cancer diagnostics.

Their ability to identify multiple cancer types from a single test enhances their value in the MCED market. Companies developing gene panels and LDTs have secured a significant position in the diagnostics field. Their focus on R&D and strategic alliances in the pharmaceutical and biotech sectors solidifies their leadership in the MCED domain. Advancements in genomics and molecular biology continue to evolve gene panels and LDTs.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$1.3 Billion
Forecast Value$4.7 Billion
CAGR14.8%

This ongoing innovation keeps these tools at the forefront of cancer detection and strengthens their position in the MCED market. The multi-cancer early detection market is segmented by end-use into hospitals, diagnostic laboratories, and other end-users. Hospitals dominated the market in 2023 with a market share of 48.2%. Patients frequently visit hospitals for routine health check-ups, diagnostics, and cancer screenings.

This makes hospitals ideal venues for integrating MCED tests into established healthcare workflows. Hospitals have multidisciplinary teams, including oncologists, pathologists, geneticists, and other specialists, who collaboratively interpret and apply MCED test results. This teamwork enhances early detection efforts and improves treatment planning. North America led the multi-cancer early detection market in 2023, generating revenues of USD 518.9 million.

Substantial investments in next-generation sequencing (NGS) and liquid biopsy technologies drive this dominance. A favorable regulatory landscape, highlighted by the FDA's breakthrough device designations for multiple MCED tests, streamlines their development and approval. Increased patient awareness and a growing demand for early cancer detection solutions further strengthen the region's leadership in the global multi-cancer early detection market.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of cancer
      • 3.2.1.2 High cancer detection rate coupled with growing demand for effective cancer tools
      • 3.2.1.3 Advancements in data analytics and artificial intelligence (AI) utilized in cancer screening
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of multi-cancer screening test
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Pipeline analysis
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Gene panel, LDT, & others
  • 5.3 Liquid biopsy

Chapter 6 Market Estimates and Forecast, By End-use, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Hospitals
  • 6.3 Diagnostic laboratories
  • 6.4 Other end-users

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
    • 7.3.6 Netherlands
    • 7.3.7 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
    • 7.4.6 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Rest of Latin America
  • 7.6 Middle East and Africa
    • 7.6.1 South Africa
    • 7.6.2 Saudi Arabia
    • 7.6.3 UAE
    • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

  • 8.1 AnPac Bio-Medical Science Co., Ltd.
  • 8.2 Burning Rock Biotech Limited
  • 8.3 EarlyDiagnostics
  • 8.4 Elypta AB
  • 8.5 EXACT SCIENCES CORPORATION
  • 8.6 Freenome Holdings, Inc.
  • 8.7 Genecast Biotechnology Co., Ltd.
  • 8.8 Guangzhou AnchorDx Medical Co., Ltd.
  • 8.9 GUARDANT HEALTH, INC.
  • 8.10 Illumina, Inc. (GRAIL, Inc.)
  • 8.11 Micronoma, Inc.
  • 8.12 Oncocyte Corporation
  • 8.13 Roche Holdings, Inc (FOUNDATION MEDICINE, INC.)
  • 8.14 SeekIn Inc.
  • 8.15 Singlera Genomics Inc